Breaking News Instant updates and real-time market news.

ALV

Autoliv

$105.52 /

-1.77 (-1.65%)

, APTV

Aptiv

$159.81 /

+0.12 (+0.08%)

08:02
01/13/22
01/13
08:02
01/13/22
08:02

Deutsche Bank sees 2022 guidance misses from these auto companies

Deutsche Bank analyst Emmanuel Rosner sees potential for "notable 2022 guidance misses" from Autoliv (ALV), Aptiv (APTV) and Visteon (VC), followed by American Axle (AXL), Lear (LEA) and Dana (DAN). Further, Adient (ADNT) is potentially a "miss and cut" candidate, Rosner tells investors in a research note previewing the Q4 earnings and 2022 outlooks for the autos and auto technology industries. On the other hand, Rosner anticipates 2022 outlooks from General Motors (GM) and Ford (F) to be "solidly in-line or above modest Street expectations." This reflects "unusual concurrent positive industry conditions of volume recovery and robust pricing, offsetting cost inflation," the analyst writes. While not providing direct guidance, he also expects a positive update from Tesla (TSLA) on its growth and margin potential in 2022 and on the cadence of its new products and technology.

ALV

Autoliv

$105.52 /

-1.77 (-1.65%)

APTV

Aptiv

$159.81 /

+0.12 (+0.08%)

VC

Visteon

$116.64 /

+0.6 (+0.52%)

AXL

American Axle

$9.64 /

-0.07 (-0.72%)

LEA

Lear

$185.58 /

-1.19 (-0.64%)

DAN

Dana

$24.13 /

-0.19 (-0.78%)

ADNT

Adient

$48.50 /

-0.925 (-1.87%)

GM

General Motors

$61.00 /

-0.46 (-0.75%)

F

Ford

$24.47 /

+0.125 (+0.51%)

  • 13

    Jan

  • 13

    Jan

  • 22

    Jan

OTHER BREAKING NEWS FROM THE FLY

Downgrade
Axon downgraded to Equal Weight from Overweight at Morgan Stanley » 06:42
05/23/22
05/23
06:42
05/23/22
06:42
AXON

Axon

$99.50 /

+1 (+1.02%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AXON Axon
$99.50 /

+1 (+1.02%)

AXON Axon
$99.50 /

+1 (+1.02%)

05/16/22 Baird
Baird downgrades three cloud stocks on focus shift to cash flows
05/12/22 Northland
Axon price target lowered to $130 from $180 at Northland
05/11/22 Baird
Axon price target lowered to $125 from $145 at Baird
05/09/22 Credit Suisse
Credit Suisse starts Axon at Outperform with $169 price target
AXON Axon
$99.50 /

+1 (+1.02%)

AXON Axon
$99.50 /

+1 (+1.02%)

Initiation
Roivant Sciences initiated with an Outperform at SVB Leerink » 06:42
05/23/22
05/23
06:42
05/23/22
06:42
ROIV

Roivant Sciences

$3.72 /

+0.075 (+2.06%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ROIV Roivant Sciences
$3.72 /

+0.075 (+2.06%)

ROIV Roivant Sciences
$3.72 /

+0.075 (+2.06%)

04/29/22 Cantor Fitzgerald
Roivant Sciences initiated with an Overweight at Cantor Fitzgerald
12/15/21 Goldman Sachs
Roivant Sciences initiated with a Buy at Goldman Sachs
12/02/21 H.C. Wainwright
H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant
11/08/21 H.C. Wainwright
Roivant Sciences initiated with a Buy at H.C. Wainwright
ROIV Roivant Sciences
$3.72 /

+0.075 (+2.06%)

ROIV Roivant Sciences
$3.72 /

+0.075 (+2.06%)

ROIV Roivant Sciences
$3.72 /

+0.075 (+2.06%)

Conference/Events
United Fire Group management to meet with Piper Sandler » 06:42
05/23/22
05/23
06:42
05/23/22
06:42
UFCS

United Fire Group

$29.42 /

-1.13 (-3.70%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UFCS United Fire Group
$29.42 /

-1.13 (-3.70%)

UFCS United Fire Group
$29.42 /

-1.13 (-3.70%)

03/21/22 Piper Sandler
United Fire Group price target raised to $37 from $30 at Piper Sandler
12/01/21 Piper Sandler
United Fire Group upgraded to Overweight from Neutral at Piper Sandler
07/09/21 Piper Sandler
United Fire Group price target lowered to $28 from $35 at Piper Sandler
06/28/21 Sidoti
United Fire Group upgraded to Buy from Neutral at Sidoti
UFCS United Fire Group
$29.42 /

-1.13 (-3.70%)

Upgrade
Zebra Technologies upgraded to Equal Weight from Underweight at Morgan Stanley » 06:41
05/23/22
05/23
06:41
05/23/22
06:41
ZBRA

Zebra Technologies

$325.57 /

+0.995 (+0.31%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZBRA Zebra Technologies
$325.57 /

+0.995 (+0.31%)

ZBRA Zebra Technologies
$325.57 /

+0.995 (+0.31%)

05/04/22 Needham
Zebra Technologies price target lowered to $500 from $535 at Needham
05/04/22 Baird
Zebra Technologies price target lowered to $440 from $550 at Baird
04/12/22 Morgan Stanley
Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious
04/12/22 Morgan Stanley
Zebra Technologies price target lowered to $400 from $470 at Morgan Stanley
ZBRA Zebra Technologies
$325.57 /

+0.995 (+0.31%)

ZBRA Zebra Technologies
$325.57 /

+0.995 (+0.31%)

ZBRA Zebra Technologies
$325.57 /

+0.995 (+0.31%)

Initiation
Alteryx initiated with an Outperform at FBN Securities » 06:41
05/23/22
05/23
06:41
05/23/22
06:41
AYX

Alteryx

$55.68 /

+0.16 (+0.29%)

FBN Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AYX Alteryx
$55.68 /

+0.16 (+0.29%)

AYX Alteryx
$55.68 /

+0.16 (+0.29%)

05/04/22 Loop Capital
Alteryx price target raised to $67 from $60 at Loop Capital
05/04/22 Cowen
Alteryx price target raised to $90 from $75 at Cowen
05/04/22 Citi
Alteryx price target raised to $95 from $86 at Citi
04/01/22 Needham
Alteryx price target raised to $86 from $66 at Needham
AYX Alteryx
$55.68 /

+0.16 (+0.29%)

AYX Alteryx
$55.68 /

+0.16 (+0.29%)

AYX Alteryx
$55.68 /

+0.16 (+0.29%)

Recommendations
April delinquency trends promising for Affirm, says Mizuho » 06:41
05/23/22
05/23
06:41
05/23/22
06:41
AFRM

Affirm

/

+

Mizuho analyst Dan Dolev…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AFRM Affirm
/

+

AFRM Affirm
/

+

05/17/22 Mizuho
Affirm price target lowered to $50 from $79 at Mizuho
05/16/22 Barclays
Affirm price target lowered to $35 from $65 at Barclays
05/13/22 RBC Capital
Affirm price target lowered to $48 from $58 at RBC Capital
05/13/22 Morgan Stanley
Affirm results reassuring, investors likely still cautious, says Morgan Stanley
AFRM Affirm
/

+

AFRM Affirm
/

+

AFRM Affirm
/

+

AFRM Affirm
/

+

Downgrade
Frontdoor downgraded to Hold from Buy at Truist » 06:41
05/23/22
05/23
06:41
05/23/22
06:41
FTDR

Frontdoor

$26.45 /

+0.245 (+0.94%)

Truist analyst Youssef…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FTDR Frontdoor
$26.45 /

+0.245 (+0.94%)

FTDR Frontdoor
$26.45 /

+0.245 (+0.94%)

05/06/22 Truist
Frontdoor price target lowered to $32 from $50 at Truist
05/06/22 Raymond James
Frontdoor price target lowered to $31 from $40 at Raymond James
05/06/22 Oppenheimer
Frontdoor price target lowered to $34 from $41 at Oppenheimer
01/06/22 Goldman Sachs
Frontdoor assumed with a Neutral at Goldman Sachs
FTDR Frontdoor
$26.45 /

+0.245 (+0.94%)

Conference/Events
Timken management to meet with Loop Capital » 06:40
05/23/22
05/23
06:40
05/23/22
06:40
TKR

Timken

$57.88 /

-0.735 (-1.25%)

Meetings to be held in CA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TKR Timken
$57.88 /

-0.735 (-1.25%)

TKR Timken
$57.88 /

-0.735 (-1.25%)

05/03/22 KeyBanc
Timken price target lowered to $75 from $84 at KeyBanc
04/13/22 Oppenheimer
Timken initiated with an Outperform at Oppenheimer
02/15/22 Evercore ISI
Timken upgraded to Outperform at Evercore ISI on relative valuation
02/15/22 Evercore ISI
Oshkosh downgraded to In Line at Evercore ISI on relative valuation
TKR Timken
$57.88 /

-0.735 (-1.25%)

Upgrade
TreeHouse upgraded to Buy from Hold at Truist » 06:40
05/23/22
05/23
06:40
05/23/22
06:40
THS

TreeHouse

/

+

Truist analyst Bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
THS TreeHouse
/

+

THS TreeHouse
/

+

03/22/22 Truist
TreeHouse price target lowered to $35 from $40 at Truist
THS TreeHouse
/

+

THS TreeHouse
/

+

Initiation
Upwork initiated with a Sector Perform at RBC Capital » 06:40
05/23/22
05/23
06:40
05/23/22
06:40
UPWK

Upwork

$18.32 /

+0.24 (+1.33%)

, MSFT

Microsoft

$252.57 /

-0.44 (-0.17%)

RBC Capital analyst Brad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UPWK Upwork
$18.32 /

+0.24 (+1.33%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

UPWK Upwork
$18.32 /

+0.24 (+1.33%)

05/17/22 Piper Sandler
'Interesting time' to be looking at Upwork story, says Piper Sandler
05/16/22 Stifel
Upwork downgraded to Hold from Buy at Stifel
04/28/22 Needham
Upwork price target lowered to $33 from $42 at Needham
04/28/22 Canaccord
Upwork price target lowered to $36 from $40 at Canaccord
MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

05/19/22 RBC Capital
Microsoft investor meetings indicate no change to macro/demand, says RBC Capital
05/13/22 Tigress Financial
Microsoft pullback 'major buying opportunity,' says Tigress Financial
05/06/22 Benchmark
Playstudios could still be target as industry consolidates, says Benchmark
04/29/22 OTR Global
Okta view downgraded to Negative from Mixed at OTR Global
UPWK Upwork
$18.32 /

+0.24 (+1.33%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

UPWK Upwork
$18.32 /

+0.24 (+1.33%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

UPWK Upwork
$18.32 /

+0.24 (+1.33%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

Initiation
Radius Health initiated with a Market Perform at SVB Leerink » 06:40
05/23/22
05/23
06:40
05/23/22
06:40
RDUS

Radius Health

$6.25 /

+0.41 (+7.03%)

, AMGN

Amgen

$247.42 /

+2.48 (+1.01%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

12/23/21 Stifel
New Radius' Tymlos label offers slight expansion potential, says Stifel
12/10/21 Morgan Stanley
Radius Health downgraded to Underweight from Equal Weight at Morgan Stanley
12/09/21 Goldman Sachs
Radius Health downgraded to Neutral from Buy at Goldman Sachs
12/09/21 H.C. Wainwright
Radius Health price target lowered to $10 from $23 at H.C. Wainwright
AMGN Amgen
$247.42 /

+2.48 (+1.01%)

06:20 Today SVB Leerink
Amgen initiated with a Market Perform at SVB Leerink
05/10/22 Mizuho
Amgen price target raised to $208 from $202 at Mizuho
05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
04/28/22 BMO Capital
Amgen price target lowered to $243 from $263 at BMO Capital
RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

RDUS Radius Health
$6.25 /

+0.41 (+7.03%)

AMGN Amgen
$247.42 /

+2.48 (+1.01%)

Hot Stocks
American Vanguard issues stockholder letter in support of director nominees » 06:38
05/23/22
05/23
06:38
05/23/22
06:38
AVD

American Vanguard

$22.31 /

-0.52 (-2.28%)

American Vanguard sent a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVD American Vanguard
$22.31 /

-0.52 (-2.28%)

Initiation
Pfizer initiated with a Market Perform at SVB Leerink » 06:38
05/23/22
05/23
06:38
05/23/22
06:38
PFE

Pfizer

$52.46 /

+1.805 (+3.56%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$52.46 /

+1.805 (+3.56%)

PFE Pfizer
$52.46 /

+1.805 (+3.56%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
PFE Pfizer
$52.46 /

+1.805 (+3.56%)

PFE Pfizer
$52.46 /

+1.805 (+3.56%)

PFE Pfizer
$52.46 /

+1.805 (+3.56%)

PFE Pfizer
$52.46 /

+1.805 (+3.56%)

Hot Stocks
Ocugen: FDA removes clinical hold on Phase 2/3 clinical trial for COVAXIN » 06:37
05/23/22
05/23
06:37
05/23/22
06:37
OCGN

Ocugen

$2.23 /

-0.01 (-0.45%)

Ocugen announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OCGN Ocugen
$2.23 /

-0.01 (-0.45%)

OCGN Ocugen
$2.23 /

-0.01 (-0.45%)

05/08/22 Chardan
Chardan keeps Neutral on Ocugen, lowers price target to $3.50
04/18/22 Roth Capital
Roth views Ocugen getting rights in Mexico as 'great news'
03/29/22 Chardan
Ocugen price target lowered to $4 from $4.50 at Chardan
03/04/22 Roth Capital
Roth says EUA denial takes accelerated Covaxin paths in U.S. off table in 2022
OCGN Ocugen
$2.23 /

-0.01 (-0.45%)

  • 23
    Feb
OCGN Ocugen
$2.23 /

-0.01 (-0.45%)

OCGN Ocugen
$2.23 /

-0.01 (-0.45%)

OCGN Ocugen
$2.23 /

-0.01 (-0.45%)

Recommendations
Nvidia price target lowered to $280 from $350 at UBS » 06:37
05/23/22
05/23
06:37
05/23/22
06:37
NVDA

Nvidia

$167.18 /

-3.95 (-2.31%)

UBS analyst Timothy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NVDA Nvidia
$167.18 /

-3.95 (-2.31%)

NVDA Nvidia
$167.18 /

-3.95 (-2.31%)

05/20/22 Wells Fargo
Nvidia price target lowered to $250 from $370 at Wells Fargo
05/20/22 Daiwa
Daiwa sees six month 'danger zone' for semiconductor stocks
05/19/22 Wedbush
Nvidia price target lowered to $190 from $300 at Wedbush
05/19/22 Oppenheimer
Nvidia price target lowered to $300 from $350 at Oppenheimer
NVDA Nvidia
$167.18 /

-3.95 (-2.31%)

NVDA Nvidia
$167.18 /

-3.95 (-2.31%)

NVDA Nvidia
$167.18 /

-3.95 (-2.31%)

NVDA Nvidia
$167.18 /

-3.95 (-2.31%)

Initiation
Eli Lilly initiated with an Outperform at SVB Leerink » 06:36
05/23/22
05/23
06:36
05/23/22
06:36
LLY

Eli Lilly

$298.98 /

+12.43 (+4.34%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$298.98 /

+12.43 (+4.34%)

LLY Eli Lilly
$298.98 /

+12.43 (+4.34%)

05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Mizuho
Eli Lilly price target raised to $356 from $315 at Mizuho
04/29/22 Morgan Stanley
Eli Lilly price target raised to $369 from $364 at Morgan Stanley
04/29/22 Wells Fargo
Eli Lilly price target raised to $305 from $280 at Wells Fargo
LLY Eli Lilly
$298.98 /

+12.43 (+4.34%)

LLY Eli Lilly
$298.98 /

+12.43 (+4.34%)

LLY Eli Lilly
$298.98 /

+12.43 (+4.34%)

LLY Eli Lilly
$298.98 /

+12.43 (+4.34%)

Downgrade
Sumitomo Pharma downgraded to Neutral from Buy at Citi » 06:36
05/23/22
05/23
06:36
05/23/22
06:36
DNPUF

Sumitomo Pharma

$9.69 /

+ (+0.00%)

Citi analyst Hidemaru…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DNPUF Sumitomo Pharma
$9.69 /

+ (+0.00%)

08/16/21 Jefferies
Sumitomo Dainippon upgraded to Buy from Hold at Jefferies
06/14/21 Jefferies
Sumitomo Dainippon downgraded to Hold from Buy at Jefferies
Periodicals
Musk's planned takeover of Twitter creates 'chaos tax,' WSJ reports » 06:34
05/23/22
05/23
06:34
05/23/22
06:34
TWTR

Twitter

$38.28 /

+1 (+2.68%)

Within 24-hours,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TWTR Twitter
$38.28 /

+1 (+2.68%)

TWTR Twitter
$38.28 /

+1 (+2.68%)

05/17/22 Wedbush
Tesla shares likely to be under pressure again Tuesday, says Wedbush
05/16/22 Wedbush
Bot issue likely excuse for lower Twitter price or Musk walks away, says Wedbush
05/16/22 Citi
Citi does not expect Twitter deal changes from spam review
05/13/22 Truist
Twitter, Musk deal could get 'messy' if he tries to walk away, says Truist
TWTR Twitter
$38.28 /

+1 (+2.68%)

TWTR Twitter
$38.28 /

+1 (+2.68%)

TWTR Twitter
$38.28 /

+1 (+2.68%)

TWTR Twitter
$38.28 /

+1 (+2.68%)

Periodicals
Electronic Arts reportedly looking to sell or merge, Kotaku reports » 06:34
05/23/22
05/23
06:34
05/23/22
06:34
EA

Electronic Arts

$130.77 /

+0.725 (+0.56%)

, CMCSA

Comcast

$41.99 /

-0.04 (-0.10%)

, DIS

Disney

$102.38 /

-0.81 (-0.78%)

, AAPL

Apple

$137.58 /

+0.26 (+0.19%)

, MSFT

Microsoft

$252.57 /

-0.44 (-0.17%)

, ATVI

Activision Blizzard

$77.40 /

-0.345 (-0.44%)

EA (EA) recently pursued…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EA Electronic Arts
$130.77 /

+0.725 (+0.56%)

CMCSA Comcast
$41.99 /

-0.04 (-0.10%)

DIS Disney
$102.38 /

-0.81 (-0.78%)

AAPL Apple
$137.58 /

+0.26 (+0.19%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

ATVI Activision Blizzard
$77.40 /

-0.345 (-0.44%)

EA Electronic Arts
$130.77 /

+0.725 (+0.56%)

05/17/22 Morgan Stanley
Take-Two price target lowered to $195 from $215 at Morgan Stanley
05/11/22 Wells Fargo
Electronic Arts price target lowered to $145 from $155 at Wells Fargo
05/11/22 Wedbush
Electronic Arts price target lowered to $164 from $180 at Wedbush
05/11/22 Cowen
Electronic Arts price target lowered to $158 from $180 at Cowen
CMCSA Comcast
$41.99 /

-0.04 (-0.10%)

05/06/22 Truist
Cable One price target lowered to $1,400 from $2,000 at Truist
04/29/22 Morgan Stanley
Comcast price target lowered to $55 from $60 at Morgan Stanley
04/29/22 Needham
Accolade price target lowered to $12 from $33 at Needham
04/29/22 Deutsche Bank
Comcast price target lowered to $60 from $62 at Deutsche Bank
DIS Disney
$102.38 /

-0.81 (-0.78%)

05:08 Today KGI Securities
Disney initiated with an Outperform at KGI Securities
05/16/22 Stifel
Trade Desk upgraded to Buy from Hold at Stifel
05/13/22 Barclays
Disney price target lowered to $130 from $168 at Barclays
05/12/22 RBC Capital
Disney price target lowered to $176 from $210 at RBC Capital
AAPL Apple
$137.58 /

+0.26 (+0.19%)

05/20/22 Wedbush
Apple a compelling name to own, ride out market storm, says Wedbush
05/19/22 BofA
BofA raises iPhone estimates, trims Apple price target to $200
05/11/22 JMP Securities
Jamf Holding price target lowered to $39 from $59 at JMP Securities
05/04/22 Benchmark
Cirrus Logic price target lowered to $95 from $100 at Benchmark
MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

05/19/22 RBC Capital
Microsoft investor meetings indicate no change to macro/demand, says RBC Capital
05/13/22 Tigress Financial
Microsoft pullback 'major buying opportunity,' says Tigress Financial
05/06/22 Benchmark
Playstudios could still be target as industry consolidates, says Benchmark
04/29/22 OTR Global
Okta view downgraded to Negative from Mixed at OTR Global
ATVI Activision Blizzard
$77.40 /

-0.345 (-0.44%)

05/06/22 Benchmark
Playstudios could still be target as industry consolidates, says Benchmark
04/25/22 Benchmark
Activision results for Blizzard 'somewhat shocking,' says Benchmark
04/19/22 Goldman Sachs
Activision Blizzard assumed with Not Rated at Goldman Sachs
02/28/22 Benchmark
Playstudios could be target as game industry consolidates, says Benchmark
EA Electronic Arts
$130.77 /

+0.725 (+0.56%)

CMCSA Comcast
$41.99 /

-0.04 (-0.10%)

DIS Disney
$102.38 /

-0.81 (-0.78%)

AAPL Apple
$137.58 /

+0.26 (+0.19%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

ATVI Activision Blizzard
$77.40 /

-0.345 (-0.44%)

EA Electronic Arts
$130.77 /

+0.725 (+0.56%)

CMCSA Comcast
$41.99 /

-0.04 (-0.10%)

DIS Disney
$102.38 /

-0.81 (-0.78%)

AAPL Apple
$137.58 /

+0.26 (+0.19%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

ATVI Activision Blizzard
$77.40 /

-0.345 (-0.44%)

EA Electronic Arts
$130.77 /

+0.725 (+0.56%)

CMCSA Comcast
$41.99 /

-0.04 (-0.10%)

DIS Disney
$102.38 /

-0.81 (-0.78%)

AAPL Apple
$137.58 /

+0.26 (+0.19%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

ATVI Activision Blizzard
$77.40 /

-0.345 (-0.44%)

EA Electronic Arts
$130.77 /

+0.725 (+0.56%)

CMCSA Comcast
$41.99 /

-0.04 (-0.10%)

DIS Disney
$102.38 /

-0.81 (-0.78%)

AAPL Apple
$137.58 /

+0.26 (+0.19%)

MSFT Microsoft
$252.57 /

-0.44 (-0.17%)

ATVI Activision Blizzard
$77.40 /

-0.345 (-0.44%)

Conference/Events
Syros Pharmaceuticals management to meet virtually with Oppenheimer » 06:34
05/23/22
05/23
06:34
05/23/22
06:34
SYRS

Syros Pharmaceuticals

/

+

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
/

+

SYRS Syros Pharmaceuticals
/

+

05/17/22 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $10 from $15 at H.C. Wainwright
05/16/22 Alliance Global Partners
Syros Pharmaceuticals price target lowered to $10 at Alliance Global Partners
03/16/22 Roth Capital
Roth 'struggles to understand' why Syros trades at $1.15 with 3 readouts ahead
01/10/22 Piper Sandler
Syros Pharmaceuticals price target lowered to $10 from $18 at Piper Sandler
SYRS Syros Pharmaceuticals
/

+

Initiation
Halozyme initiated with an Outperform at SVB Leerink » 06:34
05/23/22
05/23
06:34
05/23/22
06:34
HALO

Halozyme

$44.34 /

+0.47 (+1.07%)

, ATRS

Antares Pharma

$5.59 /

-0.005 (-0.09%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HALO Halozyme
$44.34 /

+0.47 (+1.07%)

ATRS Antares Pharma
$5.59 /

-0.005 (-0.09%)

HALO Halozyme
$44.34 /

+0.47 (+1.07%)

04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
04/13/22 Piper Sandler
Piper says Antares' auto-injector platform 'clearly complementary' for Halozyme
03/24/22 Benchmark
Halozyme 'off to a good start' to 2022 with Chugai deal, says Benchmark
ATRS Antares Pharma
$5.59 /

-0.005 (-0.09%)

04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Ladenburg
Antares Pharma downgraded to Neutral from Buy at Ladenburg
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
04/14/22 Piper Sandler
Antares Pharma downgraded to Neutral from Overweight at Piper Sandler
HALO Halozyme
$44.34 /

+0.47 (+1.07%)

ATRS Antares Pharma
$5.59 /

-0.005 (-0.09%)

HALO Halozyme
$44.34 /

+0.47 (+1.07%)

ATRS Antares Pharma
$5.59 /

-0.005 (-0.09%)

Downgrade
Realty Income downgraded to Peer Perform from Outperform at Wolfe Research » 06:33
05/23/22
05/23
06:33
05/23/22
06:33
O

Realty Income

$68.00 /

+0.84 (+1.25%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
O Realty Income
$68.00 /

+0.84 (+1.25%)

O Realty Income
$68.00 /

+0.84 (+1.25%)

03/15/22 Wolfe Research
Realty Income upgraded to Outperform from Peer Perform at Wolfe Research
01/20/22 Mizuho
Realty Income price target lowered to $76 from $82 at Mizuho
12/15/21 Scotiabank
Realty Income downgraded to Sector Perform from Outperform at Scotiabank
12/15/21 Scotiabank
Realty Income downgraded to Sector Perform from Outperform at Scotiabank
O Realty Income
$68.00 /

+0.84 (+1.25%)

  • 01
    Jul
O Realty Income
$68.00 /

+0.84 (+1.25%)

Downgrade
JBG Smith downgraded to Peer Perform from Outperform at Wolfe Research » 06:33
05/23/22
05/23
06:33
05/23/22
06:33
JBGS

JBG Smith Properties

$24.97 /

+0.045 (+0.18%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JBGS JBG Smith Properties
$24.97 /

+0.045 (+0.18%)

JBGS JBG Smith Properties
$24.97 /

+0.045 (+0.18%)

03/03/22 Evercore ISI
Evercore ISI shakes up Office REIT ratings with one upgrade, two downgrades
07/12/21 BMO Capital
JBG Smith Properties initiated with an Outperform at BMO Capital
Hot Stocks
ImmunoGen's BLA for mirvetuximab soravtansine in ovarian cancer accepted by FDA » 06:32
05/23/22
05/23
06:32
05/23/22
06:32
IMGN

ImmunoGen

$3.58 /

+0.055 (+1.56%)

ImmunoGen announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

03/21/22 RBC Capital
ImmunoGen downgraded to Sector Perform from Outperform at RBC Capital
02/10/22 BMO Capital
ImmunoGen initiated with an Outperform at BMO Capital
01/03/22 Guggenheim
ImmunoGen, Merus named 'Best Ideas' in oncology-focused biotech at Guggenheim
12/01/21 Jefferies
ImmunoGen upgraded to Buy at Jefferies after 'best-case data' in PROC
IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

  • 02
    Dec
IMGN ImmunoGen
$3.58 /

+0.055 (+1.56%)

Initiation
Johnson & Johnson assumed with an Outperform at SVB Leerink » 06:31
05/23/22
05/23
06:31
05/23/22
06:31
JNJ

Johnson & Johnson

$175.81 /

+2.97 (+1.72%)

SVB Leerink analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

05/17/22 BofA
Teva upgraded to Neutral at BofA on potential opioid deal upside
05/17/22 Citi
Johnson & Johnson price target lowered to $205 from $210 at Citi
04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

JNJ Johnson & Johnson
$175.81 /

+2.97 (+1.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.